Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietMedicationAging & DiabetesIssue 671

Metformin May Slow Aging Process

Worms treated with metformin live longer. The drug may slow the aging process by mimicking the effects of dieting....
Advertisement

A recent study grew Caenorhabditis elegans worms in the presence of E.Coli bacteria and observed the effects of metformin on the aging process. The results showed the worms that were treated with metformin had lived longer when the E.Coli strain was sensitive to the medication. In fact, the metformin increased their lifespan by 6 days, which is one-third of their usual life expectancy.

The way that metformin slows the aging process is by changing the metabolism process in the bacteria. By doing so, the bacteria restrict the nutrients that are available to the worm. This process has a similar effect to diet restriction in the body.

To isolate the metabolic pathways affected by metformin, the researchers included strains of E.Coli that had defective genes linked to metabolism and controlled the levels of nutrients available to the bacteria. The results revealed that metformin disturbed the bacteria's metabolism of folate and methionine. These are both building blocks to protein and any disruption can limit the nutrients that are available to the worm. This decrease in nutrients available to the host mimics diet restriction and allows the worm to live longer. However, when the worm was given excess sugar in its diet, the metformin did not delay the aging process.

In the gut, bacteria play an important role in nutrient digestion from food. Metabolic diseases including obesity, diabetes, inflammatory bowel disease, and cancer have been associated with defective gut bacteria. Even though metformin's anti-aging mechanism has not been proven in humans, this study may lead to future ways of preventing metabolic diseases.

Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism. Cell, 2013; 153 (1): 228 DOI: 10.1016/j.cell.2013.02.035 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2013 and appeared in  DietMedicationAging & DiabetesIssue 671

Past five issues: Issue 760 | Diabetes Clinical Mastery Series Issue 219 | SGLT-2 Inhibitors Special Edition December 2014 | Issue 759 | Diabetes Clinical Mastery Series Issue 218 |

2014 Most Popular Articles:

New Guidelines for Doctors to Treat Diabetes
Posted December 12, 2014
Handbook of Diabetes, 4th Ed., Excerpt #20: Foot Problems in Diabetes
Posted November 29, 2014
Why Are Up to 20% Type 2's Nonresponsive to Exercise?
Posted December 05, 2014
Carbs Associated with Higher Diabetes and Heart Disease Risk Factor
Posted December 05, 2014
Is Type 2 Diabetes an Inflammatory Disease?
Posted November 21, 2014
Are There Really Exercise Non-Responders?
Posted December 12, 2014
Handbook of Diabetes, 4th Ed., Excerpt #19: Macrovascular Disease in Diabetes
Posted November 23, 2014
Knowledge of Onset, Peak, and Duration of Action of Meds Prevents a Trip to the ER
Posted November 24, 2014
Any Pain Medication Said Effective When Treating Diabetic Nerve Pain
Posted November 21, 2014
Link between Free Fatty Acids and Acute MI, Type 2 Diabetes
Posted November 21, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
For your prediabetes patients who can't lower their blood glucose with lifestyle changes, do you prescribe GLP-1s or SGLT-2s?
CME/CE of the Week
Jeffrey Mechanick

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control